IP Library › Granted Patent US 12,331,107
Granted Patent B2
US 12,331,107 · App. 18/329,069 · Granted Jun 17, 2025

Methods of treating pneumonia or respiratory failure associated with COVID-19 by administering an anti-LIGHT antibody

Inventors: Garry A. Neil (Havertown, PA); Inbal Zafir-Lavie (Misgav, IL)
Assignee: Avalo Therapeutics, Inc.
C07K16/241A61K31/706A61K39/3955A61K45/06A61P1/00A61P29/00A61P31/14G01N33/6863A61K2039/505C07K2317/565C07K2317/90G01N2333/525
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,331,107
App. No.
18/329,069
Granted
Jun 17, 2025
Kind
B2
Abstract

The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.

Claims (8)

1. A method of treating pneumonia associated with COVID-19 comprising administering to a human subject in need thereof an effective amount of an anti-LIGHT antibody comprising a heavy chain and a light chain variable region comprising a CDR-H1 having the sequence of SEQ ID NO: 2, CDR-H2 having the sequence of SEQ ID NO: 3, CDR-H3 having the sequence of SEQ ID NO: 4, CDR-L1 having the sequence of SEQ ID NO: 5, CDR-L2 having the sequence of SEQ ID NO: 6, and CDR-L3 having the sequence of SEQ ID NO: 7.

2. The method of claim 1 , wherein administration of the anti-LIGHT antibody reduces serum free-LIGHT levels in the subject.

3. The method of claim 1 , wherein a single dose of about 16 mg/kg of the anti-LIGHT antibody is administered.

4. The method of claim 1 , wherein the subject has received, or is currently receiving, an anti-COVID-19 therapy comprising a corticosteroid and/or remdesivir.

5. The method of claim 1 , wherein administration of the anti-LIGHT antibody reduces the subject's risk of mortality by equal to or greater than 50% at 28 days and/or 60 days after administration.

6. The method of claim 1 , where the subject is 60 years of age or older.

7. The method of claim 1 , wherein administration of the anti-LIGHT antibody reduces the subject's risk of respiratory failure.

8. A method of treating respiratory failure associated with COVID-19 pneumonia comprising administering to a human subject in need thereof an effective amount of an anti-LIGHT antibody comprising a heavy chain and a light chain variable region comprising a CDR-H1 having the sequence of SEQ ID NO: 2, CDR-H2 having the sequence of SEQ ID NO: 3, CDR-H3 having the sequence of SEQ ID NO: 4, CDR-L1 having the sequence of SEQ ID NO: 5, CDR-L2 having the sequence of SEQ ID NO: 6, and CDR-L3 having the sequence of SEQ ID NO: 7.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2023
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: AVALO THERAPEUTICS, INC.
Reel/Frame 065547/0895 →
SECURITY INTEREST Recorded Sep 14, 2023
From: AVALO THERAPEUTICS, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 064900/0136 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2023
From: NEIL, GARRY A.; ZAFIR-LAVIE, INBAL
To: AEVI GENOMIC MEDICINE, LLC
Reel/Frame 064090/0856 →
MERGER AND CHANGE OF NAME Recorded Jun 28, 2023
From: AEVI GENOMIC MEDICINE, LLC; AVALO THERAPEUTICS, INC.
To: AVALO THERAPEUTICS, INC.
Reel/Frame 064090/0863 →
Continuity (5)
Continuation 17218449 · Mar 31, 2021
Provisional Application 63133636 · Jan 4, 2021
Provisional Application 63027127 · May 19, 2020
Provisional Application 63003826 · Apr 1, 2020
Related Publication 20240002492A1 · Jan 4, 2024
References Cited (146)
US 6998108B1 · Ware · 2006 [cited by applicant]
US 7575745B2 · Ware · 2009 [cited by applicant]
US 8058402B2 · Granger et al. · 2011 [cited by applicant]
US 8153123B2 · Ware et al. · 2012 [cited by applicant]
US 8263081B2 · Fu · 2012 [cited by applicant]
US 8349320B2 · Ware et al. · 2013 [cited by applicant]
US 8461307B2 · Granger et al. · 2013 [cited by applicant]
US 8524869B2 · Smith et al. · 2013 [cited by applicant]
US 8974787B2 · Granger et al. · 2015 [cited by applicant]
US 9301994B2 · Croft et al. · 2016 [cited by applicant]
US 9623116B2 · Fu · 2017 [cited by applicant]
US 9700606B2 · Ware et al. · 2017 [cited by applicant]
US 10407725B2 · Hakonarson et al. · 2019 [cited by applicant]
US 10525130B2 · Schnieders et al. · 2020 [cited by applicant]
US 11242564B2 · Galon et al. · 2022 [cited by applicant]
US 20130315913A1 · Zhang · 2013 [cited by applicant]
US 20130323240A1 · Smith et al. · 2013 [cited by applicant]
US 20140004106A1 · Schnieders et al. · 2014 [cited by applicant]
US 20150056182A1 · Igawa et al. · 2015 [cited by applicant]
US 20150307620A1 · Vella et al. · 2015 [cited by applicant]
US 20150337046A1 · Granger et al. · 2015 [cited by applicant]
US 20170051352A1 · Hakonarson et al. · 2017 [cited by applicant]
US 20190315876A1 · Holmes · 2019 [cited by applicant]
EP 1274840B1 · 2007 [cited by applicant]
EP 1674575B1 · 2010 [cited by applicant]
EP 1003782B1 · 2011 [cited by applicant]
EP 2207597B1 · 2020 [cited by applicant]
WO 2008027338A3 · 2008 [cited by applicant]
WO 2015107331A3 · 2015 [cited by applicant]
Steinberg, M. W., et al., “Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners” Seminars in immunopathology 31, 207-221 (2009). [cited by applicant]
Veauthier and Hornecker, “Crohn's Disease: Diagnosis and Management” Am. Fam. Physician, 98(11):661-669 (2018). [cited by applicant]
Vincent JL, et al. “The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Med… [cited by applicant]
Wang et al., “The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease” J. Immunol., 174;8173-82 (2005). [cited by applicant]
Wang, D. et al., “Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China” JAMA, 323(11):1061-1069 (2020). [cited by applicant]
Ware, C. F. “Targeting the LIGHT-HVEM pathway” Therapeutic Targets of the TNF Superfamily, 146-155 (2009). [cited by applicant]
Ware, C.F. “Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways” Immunological reviews 223, 186-201 (2008). [cited by applicant]
Ware, C.F., “Network Communications: Lymphotoxins, LIGHT and TNF” Annual Rev. Immunol., 23:787-819 (2005). [cited by applicant]
Ware, Carl F. et al., “Realigning the LIGHT signaling network to control dysregulated inflammation”, Journal of Experimental Medicine, 2022, vol. 219, No. 7. [cited by applicant]
Wroblewski, V. J. et al. “Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT” Biochemical pharmacology 65, 657-667 (2003). [cited by applicant]
Wu, F. et al. “A new coronavirus associated with human respiratory disease in China” Nature 579, 265-269 (2020). [cited by applicant]
Xiao, F. et al. “Evidence for Gastrointestinal Infection of SARS-CoV-2” Gastroenterology, 158(6):1831-1833 (2020). [cited by applicant]
Xu et al., “Transcriptome Sequencing Identifies Novel Immune Response Genes Highly Related to the Severity of Human Adenovirus Type 55 Infection” Front Microbiol 6(10):130 (2019). [cited by applicant]
Xu, Z. et al. “Pathological findings of COVID-19 associated with acute respiratory distress syndrome” The Lancet. Respiratory medicine, (4):420-422 (2020). [cited by applicant]
Yu et al., “A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis” J. Biol. Chem., 274(20):13733-6 (1999). [cited by applicant]
Cerecor Press Release on Feb. 3, 2020, retrieved from internet at https://ir.cerecor.com/press-releases/detail/87/cerecor-and-aevi-genomic-medicine-complete-merger, on Jul. 7, 2021. [cited by applicant]
Cerecor Press Release on Mar. 11, 2020, retrieved from internet at https://ir.cerecor.com/press-releases/detail/89/cerecor-reports-2019-results, on Jul. 7, 2021. [cited by applicant]
Cerecor Press Release on Mar. 26, 2020, retrieve from internet at: https://ir.cerecor.com/press-releases/detail/90/cerecor-announces-exploration-of-the-role-of-an, on Jul. 7, 2021. [cited by applicant]
Chan, JF, et al., “A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster” Lancet, 395(10223):514-523 (2020). [cited by applicant]
Channappanavar, R. & Perlman, S. “Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology” Seminars in Immunopathology 39, 529-539, (2017). [cited by applicant]
Channappanavar, R. et al. “Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice” Cell Host & Microbe 19, 181-193 (2016). [cited by applicant]
Clinical Trials, History of Changes for Study: NCT03169894; Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease, May 25, 2017; retrieved from interne… [cited by applicant]
Clinical Trials, History of Changes for Study: NCT03169894; Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease, Sep. 25, 2017; retrieved from intern… [cited by applicant]
Clinical Trials, History of Changes for Study: NCT03169894; Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease, Jun. 1, 2018; retrieved from interne… [cited by applicant]
Clinical Trials, History of Changes for Study: NCT03169894; Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease, Nov. 6, 2018; retrieved from interne… [cited by applicant]
Clinical Trials, History of Changes for Study: NCT03169894; Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease, Mar. 7, 2019; retrieved from interne… [cited by applicant]
Clinical Trials, History of Changes for Study: NCT03169894; Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease, Jul. 2, 2021; retrieved from interne… [cited by applicant]
Clinical Trials, History of Changes for Study: NCT03169894; Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease, Dec. 17, 2021; retrieved from intern… [cited by applicant]
Clinical Trials, History of Changes for Study: NCT03169894; Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis, Jan. 19, 2022;… [cited by applicant]
Clinical Trials, History of Changes for Study: NCT03169894; Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis, Feb. 24, 2022;… [cited by applicant]
Clinical Trials, History of Changes for Study: NCT04412057; Clinical Trial to Evaluate CERC-002 in Adults with COVID-19 Pneumonia and Acute Lung Injury, May 29, 2020; retrieved from internet at https://clinicaltrials.go… [cited by applicant]
Clinical Trials, History of Changes for Study: NCT04412057; Clinical Trial to Evaluate CERC-002 in Adults with COVID-19 Pneumonia and Acute Lung Injury, Mar. 1, 2021; retrieved from internet at https://clinicaltrials.go… [cited by applicant]
Clinical Trials, History of Changes for Study: NCT04412057; Clinical Trial to Evaluate CERC-002 in Adults with COVID-19 Pneumonia and Acute Lung Injury, Feb. 24, 2022; retrieved from internet at https://clinicaltrials.g… [cited by applicant]
Clinical Trials, History of Changes for Study: NCT04412057; Clinical Trial to Evaluate CERC-002 in Adults with COVID-19 Pneumonia and Acute Lung Injury, Mar. 22, 2022; retrieved from internet at https://clinicaltrials.g… [cited by applicant]
Cohavy et al., “LIGHT expression by mucosal T cells may regulate IFN-gamma expression in the intestine” J. Immunol., 2004;173(1):251-8. [cited by applicant]
Cohavy et al., “LIGHT is constitutively expressed on T and NK cells in the human gut and can be induced by CD2-mediated signaling” J. Immunol., 2005:174:646-53. [cited by applicant]
Da Silva Antunes, R. et al. “The TNF Family Molecules LIGHT and Lymphotoxin αβ Induce a Distinct Steroid-Resistant Inflammatory Phenotype in Human Lung Epithelial Cells” Journal of immunology 195(5): 2429-2441 (2015). [cited by applicant]
Da Silva Antunes, R., et al. “TNFSF14 (LIGHT) Exhibits Inflammatory Activities in Lung Fibroblasts Complementary to IL-13 and TGF-β” Front Immunol. 9:576 (2018). [cited by applicant]
Daperno M, et al.“Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD” Gastroinest Endosc. Oct. 2004;60(4):505-12. [cited by applicant]
Doherty, T. A. et al. “The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling” Nature medicine 17, 596-603, (2011). [cited by applicant]
Fehr, A. R., et al., “Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus” S. Annual review of medicine 68, 387-399 (2017). [cited by applicant]
Freeman, “Natural history and long-term clinical course of Crohn's disease” World J. Gastroenterol., 2014:20(1);31-36. [cited by applicant]
Funke et al., “Functional characterisation of decoy receptor 3 in Crohn's disease” Gut, Apr. 2009;58(4):483-91. [cited by applicant]
Graham, R. L., et al. “A decade after SARS: strategies for controlling emerging coronaviruses” Nature reviews. Microbiology 11(12): 836-848 (2013). [cited by applicant]
Gralinski, L. E. & Baric, R. S. “Molecular pathology of emerging coronavirus infections” The Journal of pathology 235, 185-195 (2015). [cited by applicant]
Granger et al., “Genomic characterization of light reveals linkage to an immune response locus on chromosome 19p13.3 and distinct isoforms generated by alternate splicing or proteolysis” J. Immunol., 2001:167:5122-28. [cited by applicant]
Guyatt et al., “A new measure of health status for clinical trials in inflammatory bowel disease” Gastroenterol., 1989:96;804-10. [cited by applicant]
Herro, R. & Croft, M. “The control of tissue fibrosis by the inflammatory molecule LIGHT (TNF Superfamily member 14)” Pharmacol Res 104, 151-155(2016). [cited by applicant]
Herro, R., et al. “Tumor necrosis factor superfamily 14 (LIGHT) controls thymic stromal lymphopoietin to drive pulmonary fibrosis” The Journal of allergy and clinical immunology 136(3): 757-768 (2015). [cited by applicant]
https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=11774 (accessed from the internet Nov. 15, 2022). [cited by applicant]
Huang, C. et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China” Lancet 395, 197-506 (2020). [cited by applicant]
Kwon, B. S. et al. “A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation” The Journal of Biological Chemistry 272, 14272-14… [cited by applicant]
Marshall, R., et al. “The acute respiratory distress syndrome: fibrosis in the fast lane” Thorax, 53(10):815-817 (1998). [cited by applicant]
Mehta, P., et al. “Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities” The Lancet, 8(8): 822-830 (2020). [cited by applicant]
O'Donnell et al., “Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate” Br. Med. J.; 300:439-40 (1990). [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US21/25068, mailed on Sep. 23, 2021, 14 pages. [cited by applicant]
Perlin et al., “Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS”, American Society for Microbiology, mSphere 5: Jul./Aug. 2020, vol. 4, Issue 4. [cited by applicant]
Perlin et al., “Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome”, J. Clin Invest. 2021, https://doi.org/10.1172/JCI153173. [cited by applicant]
Quesnel, C. et al. “Alveolar fibroblasts in acute lung injury: biological behaviour and clinical relevance” The European respiratory journal 35(6):1312-1321 (2010). [cited by applicant]
Rioux et al., “Genome wide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci” Am. J. Hum. Genet., 66:1863-70 (2000). [cited by applicant]
Sampson HA, et al. “Second symposium on the definition and management of anaphylaxis: Summary Report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium” J Allergy … [cited by applicant]
Sandoval-Montes, C. & Santos-Argumedo, L. “CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokines” Journal of leukocyte b… [cited by applicant]
Shi and Ng, “The state of the art on treatment of Crohn's disease” J. Gastroenterol., 53;989-998 (2018). [cited by applicant]
Siddiqi, H.K., et al. “COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal” J Heart Lung Transplant 39(5), 405-407 (2020). [cited by applicant]
Sostegni et al., “Review: Crohn's disease: monitoring disease activity” Aliment Pharmacolo Ther., 17 (Suppl. 2) 11-17 (2003). [cited by applicant]
Arunachalam, P.S. et al. “Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans” Science 369, 1210-1220 (2020). [cited by applicant]
Avalo Therapeutics Presentation, Aug. 2021, retrieved from internet at https://d1io3yogDoux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1109/pdf/AVTX_Initial+Crohns+Data+IR+Presentation_08262021_Fin… [cited by applicant]
Avalo Therapeutics Presentation, Aug. 2022, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_9a4f69fa787850b8da94ce1a579b1a9d/avalotx/db/282/1287/pdf/Avalo+Investor+Deck+August+2022_vf.pdf on Oct. 27, 20… [cited by applicant]
Avalo Therapeutics presentation, Jan. 2022, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_fa3474e444eb4a244813b1a27fa439a3/avalotx/db/282/1261/pdf/Avalo+Therapeutics+2022+Investor+Day+Presentation_Fin… [cited by applicant]
Avalo Therapeutics Presentation, Mar. 2022, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_9a4f69fa787850b8da94ce1a579b1a9d/avalotx/db/282/1276/pdf/Avalo+Therapeutics+Corporate+Presentation+March+2022_… [cited by applicant]
Avalo Therapeutics Presentation, Mar. 2022, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_9a4f69fa787850b8da94ce1a579b1a9d/avalotx/db/282/1245/pdf/Avalo+Therapeutics+Corporate+Presentation+March+2022_… [cited by applicant]
Avalo Therapeutics Presentation, May 2022, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_9a4f69fa787850b8da94ce1a579b1a9d/avalotx/db/282/1284/pdf/Avalo+Investor+Deck_May+2022_vFinal+%2805.25%29.pdf on… [cited by applicant]
Avalo Therapeutics presentation, Nov. 2021, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1245/pdf/FINAL+Avalo_November+IR+Deck_1109021_Post+to+AVTXcom.… [cited by applicant]
Avalo Therapeutics presentation, Oct. 2021, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1242/pdf/Avalo+IR+Deck+-+IBD+Summit+-+v101321-A.pdf on Jan. 4,… [cited by applicant]
Avalo Therapeutics Presentation, Sep. 2022, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_9a4f69fa787850b8da94ce1a579b1a9d/avalotx/db/282/1289/pdf/Avalo+Investor+Deck+September+2022.pdf on Oct. 27, 20… [cited by applicant]
Avalo Therapeutics Press Release, Aug. 13, 2020, retrieved from internet at https://ir.avalotx.com/press-releases/detail/104/cerecor-announces-peer-reviewed-publication-highlighting on Jan. 4, 2022. [cited by applicant]
Avalo Therapeutics Press Release, Aug. 2, 2021, retrieved from internet at https://ir.avalotx.com/press-releases/detail/133/cerecor-reports-second-quarter-2021-financial-results-and on Jan. 4, 2022. [cited by applicant]
Avalo Therapeutics Press Release, Aug. 26, 2020, retrieved from internet at https://ir.avalotx.com/press-releases/detail/105/cerecor-resumes-phase-1b-clinical-trial-of-cerc-002-for-the on Jan. 4, 2022. [cited by applicant]
Avalo Therapeutics Press Release, Aug. 4, 2022, retrieved from internet at https://ir.avalotx.com/press-releases/detail/157/avalo-reports-second-quarter-2022-financial-results on Oct. 27, 2022. [cited by applicant]
Avalo Therapeutics Press Release, Aug. 6, 2020, retrieved from internet at https://ir.avalotx.com/press-releases/detail/103/cerecor-reports-second-quarter-2020-financial-results-and on Jan. 4, 2020. [cited by applicant]
Avalo Therapeutics Press Release, Feb. 17, 2022, retrieved from internet at https://ir.avalotx.com/press-releases/detail/147/avalo-therapeutics-announces-leadership-transition on Oct. 27, 2022. [cited by applicant]
Avalo Therapeutics Press Release, Jan. 5, 2021, retrieved from internet at https://ir.avalotx.com/press-releases/detail/114/cerecor-announces-successful-proof-of-concept-data-for on Jan. 4, 2022. [cited by applicant]
Avalo Therapeutics Press Release, Jan. 6, 2022, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_fa3474e444eb4a244813b1a27fa439a3/avalotx/news/2022-01-06_Avalo_Reports_Positive_Phase_1b_Results_for_AVTX_… [cited by applicant]
Avalo Therapeutics Press Release, Jul. 21, 2020, retrieved from internet at https://ir.avalotx.com/press-releases/detail/99/cerecor-announces-first-patient-enrolled-in-multicenter on Jan. 4, 2022. [cited by applicant]
Avalo Therapeutics Press Release, Jul. 26, 2021, retrieved from the internet at https://ir.avalotx.com/press-releases/detail/131/cerecor-announces-positive-initial-phase-1b-results-for on Jan. 4, 2022. [cited by applicant]
Avalo Therapeutics Press Release, Mar. 2, 2021, retrieved from internet at https://ir.avalotx.com/press-releases/detail/121/cerecor-announces-cerc-002-significantly-reduced on Jan. 4, 2022. [cited by applicant]
Avalo Therapeutics Press Release, Mar. 2, 2022, retrieved from internet at https://ir.avalotx.com/press-releases/detail/148/avalo-therapeutics-reports-2021-financial-results on Oct. 27, 2022. [cited by applicant]
Avalo Therapeutics Press Release, Mar. 29, 2021, retrieved from internet at https://ir.avalotx.com/press-releases/detail/124/cerecor-announces-new-worldwide-license-agreement-with on Jan. 4, 2022. [cited by applicant]
Avalo Therapeutics Press Release, Mar. 8, 2021, retrieved from internet at https://ir.avalotx.com/press-releases/detail/123/cerecor-reports-2020-financial-results-and-provides on Jan. 4, 2022. [cited by applicant]
Avalo Therapeutics Press Release, May 11, 2021, retrieved from internet at https://ir.avalotx.com/press-releases/detail/126/fda-grants-fast-track-designation-to-cerc-002-for-treatment on Jan. 4, 2022. [cited by applicant]
Avalo Therapeutics Press Release, May 13, 2021, retrieved from internet at https://ir.avalotx.com/press-releases/detail/127/cerecor-reports-first-quarter-2021-financial-results-and on Jan. 4, 2022. [cited by applicant]
Avalo Therapeutics Press Release, May 18, 2022, retrieved from internet at https://ir.avalotx.com/press-releases/detail/152/avalo-therapeutics-announces-first-patient-dosed-in-the on Oct. 27, 2022. [cited by applicant]
Avalo Therapeutics Press Release, May 26, 2020, retrieved from internet at https://ir.avalotx.com/press-releases/detail/93/cerecor-and-myriad-genetics-announce-that-levels-of-light on Jan. 4, 2022. [cited by applicant]
Avalo Therapeutics Press Release, May 28, 2020, retrieved from internet at https://ir.avalotx.com/press-releases/detail/94/cerecor-announces-fda-clearance-of-ind-for-cerc-002-in on Jan. 4, 2022. [cited by applicant]
Avalo Therapeutics Press Release, May 5, 2022, retrieved from internet at https://ir.avalotx.com/press-releases/detail/150/avalo-therapeutics-first-quarter-2022-financial-results on Oct. 27, 2022. [cited by applicant]
Avalo Therapeutics Press Release, Nov. 9, 2020, retrieved from internet at https://ir.avalotx.com/press-releases/detail/108/cerecor-reports-third-quarter-2020-financial-results-and on Jan. 4, 2022. [cited by applicant]
Avalo Therapeutics Press Release, Nov. 9, 2021, retrieved from internet at https://ir.avalotx.com/press-releases/detail/140/avalo-reports-third-quarter-2021-financial-results-and on Jan. 4, 2022. [cited by applicant]
Avalo Therapeutics Press Release, Sep. 6, 2022, retrieved from internet at https://ir.avalotx.com/press-releases/detail/160/avalo-advances-btla-agonist-fusion-protein-avtx-008-to on Oct. 27, 2022. [cited by applicant]
Best et al. (1976) “Development of a Crohn's disease activity index, National Cooperative Crohn's Disease Study” Gastroenterol., 1976:70;439-44. [cited by applicant]
Cardinale et al., “Targeted resequencing identifies defective variants of decoy receptor 3 in pediatric-onset inflammatory bowel disease” Genes Immun. Oct. 2013:14(7):447-52. [cited by applicant]
Cerecor presentation, Aug. 2020, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1235/pdf/Updated_08102020_IR+Presentation+for+WedBush+Healthcare+Conferen… [cited by applicant]
Cerecor presentation, Biomarker Study Results, May 2020, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1231/pdf/Cerecor+COVID-19+Biomarker+Study+Results… [cited by applicant]
Cerecor Presentation, Dec. 2019, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1237/pdf/Cerecor-Aevi+Merger+Deck_01082020.pdf on Jan. 4, 2022. [cited by applicant]
Cerecor presentation, Jan. 2021, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1230/pdf/JAN_2021_IR_CERC002+COVID-19+ARDS+Trial_JAN_5_2021_+800am+FINAL%… [cited by applicant]
Cerecor presentation, Jan. 2021, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1229/pdf/Cerecor_IR+Deck+Jan+2021+Updated+7JAN_2021+FINAL+for+Cerecor+Web… [cited by applicant]
Cerecor presentation, Jul. 2021, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1227/pdf/CERC-002+Initial+Crohns+Data+Investor+Presentation.pdf on Jan. 4… [cited by applicant]
Cerecor presentation, Jul. 2021, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1226/pdf/Cerecor+July+2021+Corporate+Presentation.pptx+%281%29.pdf on Jan… [cited by applicant]
Cerecor presentation, Jun. 2020, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1233/pdf/CERC+Jefferies+Virtual+Healthcare+Conference+Presentation+Final.… [cited by applicant]
Cerecor presentation, Jun. 2021, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1142/pdf/Cerecor+Jefferies+Virtual+Healthcare+Conference+2JUNE2021.pdf on… [cited by applicant]
Cerecor presentation, Mar. 17, 2021, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1129/pdf/Cerecor+OpCo+Presentation+Deck_03172021_Final.pdf on Jan. 4,… [cited by applicant]
Cerecor presentation, Mar. 2, 2021, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1228/pdf/CERC_002_COVID_Final+Data+60+Day+Safety+Short+Deck_01032021_F… [cited by applicant]
Cerecor presentation, May 2020, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1232/pdf/Cerecor+COVID-19+ARDS+Deck+Final+_05272020+Final.pdf on Jan. 4, 2… [cited by applicant]
Cerecor presentation, Sep. 14, 2020; retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1234/pdf/Updated_09142020_IR+Presentation+for+HCWainwright+Virtual+He… [cited by applicant]
Cerecor presentation, Feb. 2020, retrieved from internet at https://d1io3yog0oux5.cloudfront.net/_38c04b70cf15803567a1dff95cd79f8d/avalotx/db/282/1236/pdf/Cerecor+IR+Deck+FEB+2020.pdf on Jan. 4, 2022. [cited by applicant]
Cerecor Press Release on Dec. 5, 2019, retrieved from internet at https://ir.cerecor.com/press-releases/detail/86/cerecor-to-acquire-aevi-genomic-medicine, on Jul. 7, 2021. [cited by applicant]
Convertino, Irma et al., “Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients”, Critical Care (2020) 24:331, 6 pages. [cited by applicant]
Ragel, Emma J. et al., “Acute respiratory distress syndrome: potential of therapeutic interventions effective in treating progression from COVID-19 to treat progression from other illnesses—a systematic review”, BMJ Ope… [cited by applicant]